Predicting the risk of malignisation of endometrial hyperplasia in reproductive age

Aim. Atypical endometrial hyperplasia (AEH) is a strong predictor of endometrial cancer, which is responsible for 80% of endometrial malignancies; out of all patients AEH, 10-50% are further diagnosed with endometrial cancer. Here we developed an algorithm for calculating the risk of AEH ma-lignisat...

Full description

Saved in:
Bibliographic Details
Main Authors: I. M. Ordiyants, A. A. Kuular, A. A. Yamurzina, D. S. Novginov
Format: Article
Language:Russian
Published: Kemerovo State Medical University 2020-03-01
Series:Фундаментальная и клиническая медицина
Subjects:
Online Access:https://fcm.kemsmu.ru/jour/article/view/221
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249094411747328
author I. M. Ordiyants
A. A. Kuular
A. A. Yamurzina
D. S. Novginov
author_facet I. M. Ordiyants
A. A. Kuular
A. A. Yamurzina
D. S. Novginov
author_sort I. M. Ordiyants
collection DOAJ
description Aim. Atypical endometrial hyperplasia (AEH) is a strong predictor of endometrial cancer, which is responsible for 80% of endometrial malignancies; out of all patients AEH, 10-50% are further diagnosed with endometrial cancer. Here we developed an algorithm for calculating the risk of AEH ma-lignisation in women of reproductive age.Materials and Methods. Our study included 143 women of reproductive age with a histologically confirmed endometrial hyperplasia. Patients were further divided into those having AEH and non-atypical endometrial hyperplasia. Control group included 56 women with abnormal uterine bleeding without endometrial hyperplasia, adeno-myosis, uterine fibroids, and cancer. We then performed binary logistic regression model for the identification of significant risk factors of AEH malignisation.Results. Among the significant risk factors were miRNA levels (miR-210, miR-18a, miR-221, miR-222), pyruvate kinase M2, pelvic inflammatory disease (OR = 7.73), adenomyosis (OR = 3.34), benign mammary dysplasia (OR = 3.21), and uterine fibroids in conjunction with adenomyosis (OR = 8.34).Conclusion. Our results show that every third patient with AEH has a risk of its malignisation to endometrial cancer. We also developed an algorithm for calculating the individual risk of such event.
format Article
id doaj-art-9aa8356a4d7342b6af11e654485316a8
institution Kabale University
issn 2500-0764
2542-0941
language Russian
publishDate 2020-03-01
publisher Kemerovo State Medical University
record_format Article
series Фундаментальная и клиническая медицина
spelling doaj-art-9aa8356a4d7342b6af11e654485316a82025-08-20T03:57:40ZrusKemerovo State Medical UniversityФундаментальная и клиническая медицина2500-07642542-09412020-03-0151576310.23946/2500-0764-2020-5-1-57-63190Predicting the risk of malignisation of endometrial hyperplasia in reproductive ageI. M. Ordiyants0A. A. Kuular1A. A. Yamurzina2D. S. Novginov3Peoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaPeoples’ Friendship University of RussiaAim. Atypical endometrial hyperplasia (AEH) is a strong predictor of endometrial cancer, which is responsible for 80% of endometrial malignancies; out of all patients AEH, 10-50% are further diagnosed with endometrial cancer. Here we developed an algorithm for calculating the risk of AEH ma-lignisation in women of reproductive age.Materials and Methods. Our study included 143 women of reproductive age with a histologically confirmed endometrial hyperplasia. Patients were further divided into those having AEH and non-atypical endometrial hyperplasia. Control group included 56 women with abnormal uterine bleeding without endometrial hyperplasia, adeno-myosis, uterine fibroids, and cancer. We then performed binary logistic regression model for the identification of significant risk factors of AEH malignisation.Results. Among the significant risk factors were miRNA levels (miR-210, miR-18a, miR-221, miR-222), pyruvate kinase M2, pelvic inflammatory disease (OR = 7.73), adenomyosis (OR = 3.34), benign mammary dysplasia (OR = 3.21), and uterine fibroids in conjunction with adenomyosis (OR = 8.34).Conclusion. Our results show that every third patient with AEH has a risk of its malignisation to endometrial cancer. We also developed an algorithm for calculating the individual risk of such event.https://fcm.kemsmu.ru/jour/article/view/221endometrial hyperplasiamirpyruvate kinase m2
spellingShingle I. M. Ordiyants
A. A. Kuular
A. A. Yamurzina
D. S. Novginov
Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
Фундаментальная и клиническая медицина
endometrial hyperplasia
mir
pyruvate kinase m2
title Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
title_full Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
title_fullStr Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
title_full_unstemmed Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
title_short Predicting the risk of malignisation of endometrial hyperplasia in reproductive age
title_sort predicting the risk of malignisation of endometrial hyperplasia in reproductive age
topic endometrial hyperplasia
mir
pyruvate kinase m2
url https://fcm.kemsmu.ru/jour/article/view/221
work_keys_str_mv AT imordiyants predictingtheriskofmalignisationofendometrialhyperplasiainreproductiveage
AT aakuular predictingtheriskofmalignisationofendometrialhyperplasiainreproductiveage
AT aayamurzina predictingtheriskofmalignisationofendometrialhyperplasiainreproductiveage
AT dsnovginov predictingtheriskofmalignisationofendometrialhyperplasiainreproductiveage